CES2 and metabolic dysfunction-associated steatotic liver disease: Our study elucidates Ces2a and CES2 as microsomal DAG and lysoPC hydrolases in vivo and suggests that aberrant hepatic lipid signaling due to decreased hepatic CES2/Ces2a expression is an important driver in the development of obesity-induced NAFLD and insulin resistance in humans and mice.